Heilbronn, Germany – August 15th, 2008
Greenovation Biotech enters into antibody glyco-engineering contract with Merck Serono.
Greenovation Biotech today announced that it has entered into an agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to evaluate antibody optimization and production in greenovation’s Bryotechnology platform.
DetailsDownload